Related Experiment Videos

Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases

Australian and New Zealand Journal of Medicine
|August 1, 1982
PubMed

Insights

Combining verapamil with beta-adrenergic blockers can cause severe cardiac issues like heart failure and low blood pressure in patients with ischemic heart disease. Discontinuing this combination therapy led to complete recovery, highlighting potential drug interaction risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Ischemic heart disease management often involves multiple medications.
  • Verapamil and beta-adrenergic blockers are commonly prescribed for cardiovascular conditions.
  • Understanding drug interactions is crucial for patient safety.

Observation:

  • Three patients with ischemic heart disease experienced severe cardiac failure, hypotension, and bradycardia.
  • These adverse events occurred during concurrent therapy with verapamil and beta-adrenergic blocking agents.
  • Symptoms resolved fully upon discontinuation of the combined drug regimen.

Findings:

  • Simultaneous administration of verapamil and beta-adrenergic blockers can lead to profound adverse cardiovascular interactions.
  • Even patients with normal or mildly reduced baseline left ventricular function were susceptible.
  • The combination therapy poses a significant risk of acute cardiac decompensation.

Implications:

  • Clinicians should exercise extreme caution when prescribing verapamil and beta-adrenergic blockers together.
  • Careful patient monitoring is essential during combined therapy.
  • This interaction necessitates a re-evaluation of current treatment guidelines for specific patient populations.

Related Concept Videos